ArticleiScience2026
Virus-host interactome reveals host cellular pathways perturbed by tick-borne encephalitis virus infection.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis virus (TBEV) poses an increasingly significant threat to public health. Building on our previous TBEV-host interactome study, we further refine the virus-host interaction network and show that multiple viral proteins, including prM, NS1, NS2B3, NS4A, and NS5, are associated with modulation of diverse host cellular pathways, including innate immune responses, autophagy, ribosomal biogenesis, homologous recombination, and cell cycle regulation. Notably, TBEV infection is associated with a modest but reproducible accumulation of host cells in the G0/G1 phase. Mechanistically, NS5 interacts with the histone acetyltransferase P300 and correlates with increased P16 expression and reduced CDK4 levels, consistent with G0/G1 cell-cycle arrest. Similar alterations were observed in TBEV-infected brain organoids. Pharmacological inhibition of P300 or activation of CDK4 attenuated virus-induced cell cycle changes and reduced viral RNA and protein levels. These findings provide valuable insights into TBEV pathogenicity and hold promise for antiviral drug development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.